Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy

Xingchun Gao1,2,3†, Yajing Mi1,2†, Na Guo1†, Hao Xu1, Lixian Xu2*, Xingchun Gou1* and Weilin Jin1,3,4*

1 Shaanxi Key Laboratory of Ischemic Cardiovascular Disease, Institute of Basic Medical Sciences, Xi’an Medical University, Xi’an, China, 2 State Key Laboratory of Military Stomatology, National Clinical Research Center for Oral Diseases, Shaanxi Engineering Research Center for Dental Materials and Advanced Manufacture, Department of Anesthesiology, School of Stomatology, The Fourth Military Medical University, Xi’an, China, 3 Department of Instrument Science and Engineering, Institute of Nano Biomedicine and Engineering, Key Lab for Thin Film and Microfabrication Technology of Ministry of Education, School of Electronic Information and Electronic Engineering, Shanghai Jiao Tong University, Shanghai, China, 4 National Centers for Translational Medicine, Shanghai Jiao Tong University, Shanghai, China

Cytokine-induced killer (CIK) cells are a heterogeneous population of effector CD3+CD56+ natural killer T cells, which can be easily expanded in vitro from peripheral blood mononuclear cells. CIK cells work as pharmacological tools for cancer immunotherapy as they exhibit MHC-unrestricted, safe, and effective antitumor activity. Much effort has been made to improve CIK cells cytotoxicity and treatments of CIK cells combined with other antitumor therapies are applied. This review summarizes some strategies, including the combination of CIK with additional cytokines, dendritic cells, check point inhibitors, antibodies, chemotherapeutic agents, nanomedicines, and engineering CIK cells with a chimeric antigen receptor. Furthermore, we briefly sum up the clinical trials on CIK cells and compare the effect of clinical CIK therapy with other immunotherapies. Finally, further research is needed to clarify the pharmacological mechanism of CIK and provide evidence to formulate uniform culturing criteria for CIK expansion.

Keywords: cytokine-induced killer cells, immunotherapy, pharmacological tools, cancer therapy, clinical trials

INTRODUCTION

Cancer is among the top killer diseases and has emerged as a major public health problem around the world, and it will still be the main cause of the morbidity and mortality during the next few decades (1). Bray et al. estimated that the incidence of all cancer cases would up to 22.2 million in 2030 (2). In order to cure cancer, researchers have tried many antitumor strategies, but the recurrence and mortality rate of cancer are still high. Adoptive immunotherapy, as an adjuvant or alternative treatment, holds great promise in treating various malignant tumors. Cytokine-induced killer (CIK) cells are considered to be an ideal candidate cell type for cancer immunotherapy. A lot of basic researches and clinical studies show the safety and feasibility of CIK therapy in treating malignant tumors. Combination of CIK with either immunological or genetic engineering approaches have been made to improve the effects of CIK and all the key events in the history of CIK immunotherapy are shown in Figure 1 (3–16). In this review, the research progress and clinical application of CIK are summarized.
WHAT IS CIK?

Cytokine-induced killer cells were first discovered in 1991 (5) and are a heterogeneous population of CD8+ T cells, which were generated from human peripheral blood lymphocytes (PBLs) and simply expanded \textit{ex vivo} via incubation with an anti-CD3 antibody, interferon-γ (IFN-γ), and interleukin (IL)-2. They can kill tumor cells mediated by FasL and perforin (17). According to the presence of cell surface molecule CD56, CIK cells are also divided into two main subsets: CD3+CD56+ T cells and CD3+CD56− T cells (18). CD3+CD56+ T cells, which are also called the natural killer T cells, are considered to be the major effector cells of CIK. So, CIK cells can lyse cancer cells in a MHC-unrestricted manner through activating NK cell receptors such as DNAX accessory molecule-1, NKp46, NKG2D, and NKp30 (11, 19, 20). In addition to the direct killing effect of CIK on cancer cells, they can also regulate the immune function by secreting various cytokines. A lot of studies have indicated that after stimulation by tumor cells, the levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, IFN-γ, and IL-2 secreted by CIK cells are significantly upregulated (21), and these cytokines further enhance systemic antitumor activity.

EX VIVO EXPANSION AND ALLOREACTIVITY OF CIK CELLS

Obtaining a sufficient number of antitumor immune cells is a critical step in the successful application of CIK cell immunotherapy (22). Fortunately, CIK cells can be easily expanded \textit{in vitro} from peripheral blood mononuclear cells (PBMC), and some reports also showed that they could be also generated from umbilical cord blood precursors or bone marrow (23, 24). The general culture protocol for the \textit{ex vivo} expansion of CIK cells requires 3–4 weeks with the addition of IFN-γ, anti-CD3 antibody, and IL-2. And the detail steps are as follows: on day 0, the PBMC are separated by density-gradient centrifugation from the whole blood (24, 25) and treated with IFN-γ to activate macrophages, which further provide cytokine-mediated (IL-12) and contact-dependent (CD58/LFA-3) signals to promote the cytotoxic power of CIK cells (26–28). On day 1, anti-CD3 antibody and IL-2 are added to the medium. Anti-CD3 will provide mitogenic signals for T cells which are then sustained by the continuous presence of IL-2 (29, 30). Fresh medium with IL-2 is added every 2 days. After 3–4 weeks of culture, the generated CIK cells are subsequently infused back into patients (Figure 2). The amount of injected CIK cells varied in different studies, so did the cell expansion rates. In fact, the average final expansion rates were usually in a range of 100-fold, but individual expansion rate was described to be variable from few to more than 1,000-fold (5, 25, 31, 32). It is well known that the more the CIK cells are injected and expanded, the better they respond. Hontscha et al. showed that the total number of injected CIK cells ranged from $21.9 \times 10^7$ to $5.2 \times 10^{10}$ (14), Li et al. found the total number of CIK cells ranged from $6 \times 10^6$ to $1.5 \times 10^{10}$ in Chinese clinical trials (33). Until now, the least injected number of CIK cells was reported to be $6 \times 10^6$ to obtain an objective response. Cohen et al. considered that tumor-infiltrating lymphocytes (TILs) must be expanded to $10^{10}$ for a successful treatment (34). Therefore, $\sim 10^{10}$ CIK cells might be a good choice and many studies used more than $1 \times 10^{10}$ cells to transfuse into the patients. As mentioned above, the reason why CIK expansion rate varies greatly is unclear. But there are still some additional strategies under investigation to further improve the expansion of CIK cells (22), which include adding new cytokines to the culture medium, such as IL-1, IL-7, IL-15, or thymoglobulin (8, 35, 36).

Cytokine-induced killer immunotherapy, a personalized therapy that uses patients’ own PBMC to expand antitumor CIK cells which are then reinjected into patients themselves, rarely causes autoimmune response. But sometimes, it is very difficult to obtain a sufficient number of CIK cells due to the poor health situation of patients, such as elderly people and patients with immunodeficiency diseases (37). To solve this problem, getting CIK cells from donor PBMC seems to be an alternative option. Studies showed that CIK cells exhibited a decreased alloreactivity across HLA barriers that could further reduce the risk of graft-versus-host disease (GVHD). Many phase I clinical studies
proved that infusion of the allogeneic CIK cells in patients relapsing after allogeneic hematopoietic cell transplant would reduce the incidence of GVHD events (38–40). Another solution to obtain sufficient CIK cells is collecting from the cord blood. Mature protocols have already been made for generation of cord blood-derived CIK (CB-CIK) cells (41). The CB-CIK cells displayed relatively lower expression of HLA, indicating a weaker immunogenicity and lower risk of GVHD (42). Many clinical trials proved that CB-CIK cells were effective and safe to patients with malignancies (43, 44). All these suggest that CIK is a safe immune therapy with lower risk of GVHD.

IMPROVED CIK THERAPY

In the last decade, CIK cells have begun to be used in clinical care with good prospects for treatment success, and a great deal of research has been done to improve their cytotoxicity and safety. Here, we have summarized the current improved CIK therapies (Figure 3) (45, 46).

CIK Combined with Additional Cytokines

Cytokine-induced killer cells are a heterogeneous cell population that can be expanded \textit{ex vivo} from PBMC with the addition of IFN-γ, anti-CD3 antibody, and IL-2. In fact, many additional cytokines have been made to improve CIK antitumor activity. These cytokines can improve cell proliferation and cytotoxicity partly by suppressing the generation of regulatory T (Treg) cells that are known to inhibit antitumor immunity.

Lu et al. reported a new protocol for expansion of highly efficient cytotoxic CIK cells by culturing PBLs with addition of IL-1α (23). Another research showed that addition of IL-6 could significantly decrease the percentage of Treg cells and simultaneously increase the proliferation ability and cytotoxicity of the CIK cells against hepatocellular carcinoma (HCC) \textit{in vitro} (47). By transfecting IL-7 gene expression vector into CIK cells, Finke et al. demonstrated an improved proliferation rate and enhanced antitumor cytotoxicity of CIK cells (48). Further study showed an upregulation of LFA-1 (CD11a/CD18) and CD28 in CIK cells with the addition of exogenous IL-7, which were essential for cytotoxic activity of CIK and played an important costimulatory role in T cell activation, respectively (49).

As an immune stimulatory cytokine, IL-12 has the strongest antitumor activity that can induce a Th1 type of response and active NK and cytotoxic T lymphocyte (CTL) cells (50). CIK cells, generated with exogenous IL-12 instead of IL-2, showed similar cytotoxicity (8). However, due to its high toxicity, a lower dose of IL-12 should be used in combination with CIK in clinical application (50). Many studies demonstrated that CIK cells stimulated with IL-15 displayed improved proliferation capacity and cell cytotoxicity against hematologic and solid malignancies (36, 51–55). And a possible mechanism for its function might be the regulation of Treg cells and the expression of toll-like receptor 4, Wnt 4, PDGFD, and IL-35 (51, 56, 57). Application of IL-21 did not increase the proliferation rate of CIK cells (58, 59), but the cell cytotoxicity was significantly enhanced by increasing expression of IFN-γ, TNF-α, perforin, and granzyme B.

Dendritic Cell (DC)–CIK

Dendritic cells are professional antigen-presenting cells (APCs) that can capture and process tumor-associated antigens (TAAs) (60). Given their particular ability to stimulate both adaptive
and innate antitumor immune responses, DCs have been used as a powerful pharmacological tool for cancer immunotherapy (61). Many researches showed that DCs could promote NK cell-dependent antitumor effects through a cell-to-cell contact (62, 63). In recent years, studies have focused on the combinational treatment of DCs and CIK cells and proved a relative more safe and effective therapeutic effect on advanced solid carcinoma, which provide a new and efficacious immunity therapeutic strategy for cancer treatment. Cao et al. showed that coculture of CIK cells with DCs in vitro could improve the proliferation rate and antitumor activity of CIK cells (64). Further studies showed that the cellular interactions between CIK cells and DCs led to changes in the surface molecule expression of both populations and a significant increase of IL-12 secretion, and finally resulted in a higher cytotoxic activity of CIK cells (10). Pan et al. reported that DCs decreased the concomitant expanded Tregs in CIK cells and enhanced the cytotoxicity of CIK cells against leukemia cells (65). As we all know, delivering TAAs to DCs as vaccines have been reported to be an effective strategy for the treatment of various advanced malignancies. The combination of DCs vaccination with CIK cells is considered to be more prospected, and studies showed a significantly stronger antitumor activity and fewer side effects (17, 66–69). Jung et al. showed that in an in vivo animal model, the CIK + DC vaccination therapy was more effective than CIK or DC vaccination alone therapy for the treatment of hepatocarcinoma tumor cells (70). More recently, Lin et al. reported that DC–CIK therapy could improve survival by reducing the risk of disease progression in stage IV breast cancer patients (71).

**CIK Combined with Immune Checkpoint Inhibitors**

Immune checkpoints are molecules that can either turn up or turn down signals in immune system. When CTLs recognize and trigger tumor cell death by inducing apoptosis, various checkpoint pathways between APCs/tumor cells and T cells are activated to provide signals for T cell activation (72, 73). There are at least two signaling pathways regulating the activation or inhibition of the CTLs: the primary signal is the binding occurred between peptide–MHC which is presented by APCs and T cell receptors. The secondary signal is the costimulatory/coinhibitory signal that regulates T cell activation (74, 75). The CD28, OX40, CD58, CD40L, CD80, CD86, and CD137 are stimulators that can promote immune activation, whereas programmed death 1 (PD-1), cytotoxic lymphocyte-associated antigen 4 (CTLA-4), lymphocyte
activation of antigen 3 (LAG-3), T cell immunoreceptor with Ig and ITIM domains, and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) are inhibitors that suppress immune activation. CTLA-4 and PD-1 involved in the T-cell immune evasion in many malignancies, thus they are always designed as targets for cancer immune therapies (16, 76). It has been demonstrated that the blockade of inhibitory receptors such as PD-1, KIR, TIM-3, and LAG-3 but not CTLA-4 on CIK cells can significantly increase their antitumor potency against hematological malignancies. However, the combination of inhibitors against two receptors showed no increased cytotoxicity compared to that of one alone (77). Dai et al. reported that the blockade of PD-L1/PD-1 augmented CIK cytotoxicity against gastric and colorectal cancer cells. Additionally, combined therapy of CIK with checkpoint inhibitors (PD-L1/PD-1 blockade) could inhibit tumor growth and prolong the survival in the murine model of gastric cancer compared to untreated mice (16). All these suggest that combination of CIK cells with checkpoint inhibitors will be a novel immunotherapy for cancer treatment.

**CIK Combined with Antibodies**

Immunotherapy of tumors with specific antibodies has been established as one of the most successful therapeutic strategies in the last 20 years. The mechanisms of antibody-based tumor cell killing are as follows: (1) antibody can directly bind to the cell surface receptor, deliver drug or toxin to target tumor cells, induce cell apoptosis, and reduce proliferation; (2) antibody can kill tumor cells by immune-mediated killing mechanisms such as activating complement, antibody-dependent cellular cytotoxicity, and regulating T cell function; (3) antibody can regulate tumor angiogenesis by vasculature receptor antagonism or ligand trapping (78, 79). Many studies showed that CIK cells combined with antibody could improve their cytolytic activity. Plevani et al. reported that addition of anti-CD20 mAb rituximab or GA101 could significantly enhance cytotoxicity of CIK cells to B-cell lymphoma in vitro (20). Deng et al. further proved that the enhanced CIK cytotoxicity induced by anti-CD20 mAb was partly related to the increased expression of components of the MAPK/ERK and STAT signaling pathways (80). Esser et al. reported that the combinational treatment of CIK cells with anti-CD30 mAb Brentuximab Vedotin (SGN-35) achieved better efficacy in CD30+ lymphoma, and SGN-35 did not affect the function of CIK cells (81). Besides, bispecific antibodies (BsAbs) that have two different antigen-binding sites could improve adoptive immunotherapy effect by cross-linking CIK cells with malignant tumor cells (82). BsAb CD19 × CD5 (HD37 × T5.16) has been reported to increase the cytolytic activity of CIK cells against B-lymphoma cells (83). BsAbs against cancer antigen-125 and Her2 significantly enhanced the cytotoxicity of CIK cells in primary ovarian cancer in both in vitro and in vivo models (84). BsAb EGFR/CD3 could improve the cytotoxic activity of CIK cells toward gastric cancer cells (85). When combined with anti-CD3/anti-CD133 BsAb, CIK cells showed significantly stronger cytotoxicity to CD133+ pancreatic and hepatic cancer cells than that of CIK, CD3-CIK, or BsAb alone (86). Recently, Ma et al. reported that CIK cells armed with BsAb CD3 × EGFR (EGFRBi-Ab) to target EGFR-positive glioblastoma significantly increased CIK cells cytotoxic activity in vitro and inhibited the growth of glioblastoma tumors in glioblastoma xenograft mice (87). All these data suggest a better in vitro and in vivo antitumor effect of CIK cells combined with antibodies, which will definitely provide a novel useful method for the CIK cells.

**CIK Combined with Chimeric Antigen Receptor (CAR)**

To promote target cell recognition and improve specific cytotoxicity of CIK, CIK cells are always engineered with a CAR that is targeted to specific antigen. CIK cells engineered with a CAR that was directly targeted against carcino-embryonic antigen (CEA) showed improved activation toward CEA+ colon carcinoma cells, compared to that of CEA- cells (15). Oelsner et al. proved that CD19 CAR-engineered CIK cells could dramatically enhance their antileukemic activity (88). Remarkably, Marin et al. found that CIK cells combined with CD19-target CARs containing a costimulatory CD28 or 4-1BB domain together with CD3ζ exhibited better antitumor effect than CARs based on DAP10 or CD3ζ alone (89, 90). Likewise, Hombach et al. reported that CIK cells arming with CD28-CD3ζ CAR showed stronger cytotoxicity; however, CIK cells arming with the third-generation CD28-CD3ζ-OK4 CAR that provided a super costimulation signal exhibited less antitumor efficacy due to increased activation-induced cell death (91). All these data indicate that CIK cells modified by CAR have stronger tumor cell killing activity, and the appropriate design for CAR is crucial for the successful application of CAR-mediated CIK response.

**CIK Combined with Chemotherapy**

Many studies have shown that CIK/DC–CIK combined with different chemotherapeutic strategies for cancer treatment exhibited better efficacy than chemotherapy alone. Wu et al. showed that CIK cells plus chemotherapy (docetaxel and cisplatin) could significantly prolong the progression-free survival (PFS) and overall survival (OS) in advanced non-small-cell lung cancer (NSCLC) patients (92). Niu et al. proved that CB-CIK cells combined with second-line chemotherapy drug (dexamethasone) could improve PFS and OS in patients with advanced solid malignancies after first-line chemotherapy failure (44). As we all know, chemoresistance is a major problem to be solved in the treatment of cancers. Interestingly, many studies showed that the combination of CIK with chemotherapy could overcome chemotherapy resistance by activating the immune system (93, 94). Zheng and Han analyzed the efficiency and safety of chemotherapy combined DC with CIK cells in the treatment of NSCLC using meta-analysis. They found that chemotherapy combined with DC–CIK immunotherapy was superior in 1-year OS, disease control rate (DCR), and disease-free survival (DFS). Meanwhile, no more adverse events (AEs) appeared. However, there was no obvious improvement in objective response rate (ORR), partial response, 2-year PFS, and OS. All these suggested the combination therapy was modest in efficacy and safer for advanced NSCLC patients (95, 96). Similar results, with significantly prolonged 1–5 year OS, DFS, and improved DFS, ORR, and DCR with the infusion of CIK/DC–CIK combined with chemotherapy was reported by Mu
et al. in patients with gastric cancer. Moreover, the levels of IFN-γ and IL-12, except IL-2, significantly increased after CIK/DC-CIK therapy, proving that the immune function of gastric cancer patients also significantly improved (97). Another meta-analysis proved that DC-CIK combined with chemotherapy could prolong 1-year OS, 2-year OS, and 3-year OS on colon cancer (98). All these data indicate an antitumor effect of CIK and chemotherapy in comparison with the use of chemodrugs or CIK cells alone.

**CIK Combined with Nanomedicine**

With the rapid development of nanotechnology and nanomedicine, nanomaterials have been applied in various fields, especially in human health care. In recent years, nanotechnology has brought many new methods for cancer treatment (99–103). Nanometer-sized particles (1–100 nm) are in the same range of dimension as biomacromolecules including antibodies and membrane receptors (104). Their inherent physical/chemical properties or being loaded with different imaging/therapeutic agents in their surface, all of which make nanoparticles become a powerful tool for diagnosis, imaging, and therapy (105–107). Importantly, nanomaterials with low toxicity can be used as vaccine carrier/adjuvant to improve the immunogenicity of antigens by enhancing their cellular uptake, preventing enzyme degradation, and regulating the immune cells function (108, 109). Many researchers explored the potential applications of nanomaterials in monitoring the trafficking of DCs and enhancing the efficacy of DC-based cancer vaccines, such as quantum dots (110), magnetic nanoparticles (111–114), and upconversion nanoparticles (115). Furthermore, it has been reported that nanoparticles could also work as cancer vaccines (116), and these cancer nanovaccines could be envisioned as nanocarriers codelivering antigens and adjuvants (117–119). As we discussed, the efficacy of DC-CIK is better than DC or CIK alone, so we propose that the combination of CIK/DC-CIK cells with nanomaterials may have a great potential in cancer immunotherapy.

**CLINICAL TRIALS ON CIK CELLS**

At present, CIK as a pharmacological tool for cancer therapy has been tested in clinical trials of various tumors. 90 registered clinical trials have been found on the website ClinicalTrials.gov (http://www.clinicaltrials.gov) (Table 1) by searching the keywords: cytokine-induced killer cells or CIK. One trial is working on psoriasis (Table 1). The majority of these are concentrated in China (58 studies), followed by 6 studies in U.S., 3 studies in Singapore, and 3 studies in Korea. Besides, two trials (NCT01533727, NCT02539017) have been withdrawn, 1 trial terminated (NCT01871480), 22 trials have been completed. Below, we will summarize these clinical trials on CIK cells.

In a first Phase I study, Schmidt-Wolf et al. demonstrated the safety and initial activity of CIK in therapeutic trials (9). In addition, CIK cells could be successfully expanded from patients treated with or without chemotherapy (120), so CIK cells were widely applied to treat various types of tumors including HCC, lung cancer, and gastrointestinal tumors (Table 1).

Lee et al. reported that patients who received CIK immunotherapy after curative treatment for HCC had a 14-month median recurrence-free survival (RFS) benefit (121). The OS and cancer-specific survival were longer in the immunotherapy group compared to the control group. The ratio of AEs was significantly higher in the immunotherapy group (P = 0.002), but there was not a significant difference in the proportion of patients with serious AEs between groups (P = 0.15) (NCT00699816). It is worth noting that previous studies about CIK therapy for HCC showed significant benefits in preventing recurrence, but no significant survival gains (122–124). The difference of these results may be due to several aspects, such as the different intensified schedule of CIK, different cancer clinical stage or the non-standard quality of CIK cells (commercialized CIK cell compared to uncommercialized CIK cells). Lee et al. proved that adjuvant immunotherapy with activated CIK cells could increase the RFS and OS of patients who suffered with HCC (125) (NCT00699816). Furthermore, adjuvant CIK cells treatments were proved to be safe and effective for HCC treatment by several meta-analyses (126–129).

In 2012, a phase II clinical study showed that CIK immunotherapy could enhance the efficacy of conventional chemotherapy in patients with NSCLC (130). Furthermore, Chen et al. proved that the MHC class I-related chain A (MICA) status was also associated with the outcome measures in CIK therapy for patients with prostate cancer, for the patients with high expression of MICA were more likely to benefit from CIK therapy (131, 132). In a phase II/III study, combined radiofrequency ablation with CIK has been reported to be a safe and effective treatment for CRLMs patients (133). Hereafter, many clinical studies were conducted to evaluate the efficacy of CIK/DC-CIK cell therapy for lung cancer, and all the results showed that CIK/DC-CIK was an effective therapy for lung cancer (134–139).

Many researches proved that CIK therapy was therapeutic for treatment of gastrointestinal tumors such as colorectal cancer and gastric cancer. In 2014, a meta-analysis in China showed that the combination of DC-CIK with chemotherapy could significantly improve the survival benefit, DFS rate, and overall response rate in patients with colon cancer. Furthermore, the number of CD4+ T cells was significantly increased in the DC-CIK + chemotherapy group (98). Zhao et al. reported that CIK cells could improve OS of metastatic colorectal cancer patients in a phase II clinical trial (140). Lin et al. showed that DC-CIK combined with chemotherapy could prolong PFS and OS in colorectal cancer patients compared to chemotherapy alone (141). Mu et al. summarized 17 eligible trials including 1,735 patients with gastric cancer in a meta-analysis, and they found that the combination of chemotherapy with CIK/DC-CIK significantly increased the OS rate and DFS rate, enhanced immune function, and reduced the AEs caused by chemotherapy (97). Kong et al. showed that the addition of CIK cells immunotherapy to standard chemoradiotherapy with temozolomide improved PFS but not OS in a phase III randomized trial of newly diagnosed glioblastoma in Korea (142) (NCT00807027).

The clinical outcome of cancer with different pathologic stages is different, but little is known about the achievable outcome of CIK cells in patients with different pathological stages of the tumor. Recently, Li et al. reported that combined CIK with
| Trial | Phases | Experimental design | Target disease | Recruitment | Enrollment |
|-------|--------|---------------------|----------------|-------------|------------|
| NCT01537327 | II | CIK + chemotherapy | Non-small-cell lung cancer (NSCLC) | Withdrawn | 0 |
| NCT02359017 | II | Dendritic cell (DC)/CIK + chemotherapy | Triple-negative breast neoplasms | Withdrawn | 0 |
| NCT01871480 | II | CIK + gefitinib | NSCLC | Terminated | 50 |
| NCT01656528 | II | CIK + chemotherapy | Nasopharyngeal carcinoma | Recruiting | 40 |
| NCT01902287 | II | CIK + chemotherapy | NSCLC | Recruiting | 100 |
| NCT01914263 | II | CIK | Solid tumor | Recruiting | 40 |
| NCT01868490 | II | CIK | Cholangiocarcinoma | Recruiting | 13 |
| NCT01186809 | II | CIK | Hematologic malignancies | Recruiting | 50 |
| NCT01839539 | II | DC–CIK | Colorectal cancer | Recruiting | 60 |
| NCT02539017 | II | Dendritic cell (DC)/CIK + chemotherapy | Solid tumors/B cell lymphoma | Recruiting | 100 |
| NCT01871480 | II | CIK + gefitinib | NSCLC | Terminated | 100 |
| NCT01655628 | II | CIK + chemotherapy | Lung adenocarcinoma | Recruiting | 280 |
| NCT02280278 | III | Radical surgery/adjuvant chemotherapy + CIK | Colon cancer | Recruiting | 550 |
| NCT01592422 | II | CIK | Small-cell lung cancer | Recruiting | 60 |
| NCT01498055 | II | CIK | Lung cancer | Recruiting | 120 |
| NCT01481259 | II/III | CIK | Hematologic malignancies | Recruiting | 100 |
| NCT01868490 | II | DC–CIK | Colorectal cancer | Recruiting | 100 |
| NCT01896593 | II | CIK | Cholangiocarcinoma | Recruiting | 60 |
| NCT01186809 | II | DC–CIK | Cholangiocarcinoma | Recruiting | 13 |
| NCT01186809 | II | CIK | Hematologic malignancies | Recruiting | 50 |
| NCT01839539 | II | DC–CIK | Colorectal cancer | Recruiting | 60 |
| NCT02539017 | II | Dendritic cell (DC)/CIK + chemotherapy | Solid tumors/B cell lymphoma | Recruiting | 100 |
| NCT01871480 | II | CIK + gefitinib | NSCLC | Terminated | 100 |
| NCT01655628 | II | CIK + chemotherapy | Lung adenocarcinoma | Recruiting | 280 |
| NCT02280278 | III | Radical surgery/adjuvant chemotherapy + CIK | Colon cancer | Recruiting | 550 |
| NCT01592422 | II | CIK | Small-cell lung cancer | Recruiting | 60 |
| NCT01498055 | II | CIK | Lung cancer | Recruiting | 120 |
| NCT02752243 | II | CIK | Myelodysplastic syndromes (MDS)/acute leukemia | Recruiting | 40 |

(Continued)
### TABLE 1 | Continued

| Trial     | Phases | Experimental design | Target disease                          | Recruitment | Enrollment |
|-----------|-------|---------------------|------------------------------------------|-------------|------------|
| NCT02450435 | Undefined | DC-CIK + cryosurgery | Neoplastic cells, circulating            | Completed   | 60         |
| NCT02450422 | Undefined | DC-CIK + cryosurgery | Neoplastic cells, circulating            | Completed   | 60         |
| NCT02425735 | I/II  | DC–CIK + γδ T       | Liver cancer                             | Completed   | 40         |
| NCT0807027 | I/II  | CIK + chemotherapy  | Glioblastoma                             | Completed   | 180        |
| NCT01395056 | Undefined | DC–CIK + chemotherapy | Triple-negative breast cancer            | Completed   | 23         |
| NCT02425748 | I/II  | DC–CIK + γδ T       | Lung cancer                              | Completed   | 40         |
| NCT02418481 | I/II  | DC–CIK + γδ T       | Breast cancer                            | Completed   | 40         |
| NCT0699816 | III   | CIK                  | Hepatocellular carcinoma                 | Completed   | 230        |
| NCT01866342 | Undefined | CIK                  | Hematologic malignancies                | Completed   | 120        |
| NCT02482454 | I/II  | Radiofrequency ablation + CIK | Cholangiocarcinoma                       | Active, not recruiting | 50         |
| NCT01392869 | III   | CIK + chemotherapy   | MDSs                                     | Active, not recruiting | 44         |
| NCT02490890 | III   | CIK                  | Urinary bladder neoplasms               | Active, not recruiting | 1,500      |
| NCT0185577 | III   | CIK                  | Multiple myeloma                         | Active, not recruiting | 20         |
| NCT02485015 | I/II  | CIK + apatinib       | Stomach neoplasms                       | Active, not recruiting | 80         |
| NCT02490748 | I/II  | Radiofrequency ablation + CIK | Cervical cancer                          | Active, not recruiting | 10         |
| NCT02493582 | III   | CIK + apatinib       | Adenocarcinoma of lung                   | Active, not recruiting | 400        |
| NCT02215837 | I/II  | Chemotherapy + DC-CIK | Gastric cancer                           | Active, not recruiting | 40         |
| NCT01924156 | I/II  | adenovirus-transfected DC + CIK | Renal cell carcinoma                    | Active, not recruiting | 30         |
| NCT01898663 | I/II  | adenovirus-transfected DC + CIK | High-risk soft tissue sarcoma            | Active, not recruiting | 30         |
| NCT02491697 | I/II  | DC–CIK + capecitabine monotherapy | Breast cancer                           | Active, not recruiting | 400        |
| NCT02487693 | I/II  | Radiofrequency ablation + CIK | Ovarian carcinoma                        | Active, not recruiting | 50         |
| NCT02487992 | III   | CIK                  | Colorectal neoplasms                     | Active, not recruiting | 1,200      |
| NCT02693236 | I/II  | adenovirus-transfected autologous DC + CIK | Esophage cancer                         | Active, not recruiting | 30         |
| NCT0220928 | II/III | DC–CIK + chemotherapy | Colorectal cancer                        | Active, not recruiting | 60         |
| NCT01956650 | II/III | DC–CIK | Acute leukemia                          | Active, not recruiting | 25         |
| NCT02688673 | II/III | DC–CIK | Small-cell lung cancer                  | Active, not recruiting | 30         |
| NCT02678013 | I/II  | RFA + highly purified cytotoxic T lymphocytes | HCC                                    | Active, not recruiting | 210        |

These data were searched on 11 August, 2016 from the ClinicalTrials.gov (http://www.clinicaltrials.gov) using the word “cytokine-induced killer cells OR CIK.”

conventional treatments could increase the survival rate of early-stage melanoma patients (143). So, whether the outcome of CIK is better in early-stage patient needs to be further studied.

As we have seen, most of the CIK registered clinical trials are restricted to Asian countries (64 trials), so it is difficult to completely evaluate the effects of CIK therapy over the world. Besides, the number of patients included in some clinical trials is also inadequate. So, more large-scale, grouped, controlled, multicenter, non-commercial clinical trials are required to confirm the immunotherapeutic effects of CIK in cancer treatment.

**CONCLUSION AND PROSPECTS**

In recent years, immunotherapy is considered to be a powerful pharmacological tool for the treatment of many malignancies (144). It is known that the expression of tumor antigens and MHC-I molecules are often downregulated or completely lost on tumor cells. Although the TILs could recognize specific antigens expressed by autologous tumor cells, this specific antigenicity is too low to achieve a high degree of antigenicity in therapeutic use (120, 145). What is more, the extremely low numbers of TIL cells and lymphokine-activated killer (LAK) cells also restrict their application. Compared to LAK cells, the CIK cells exhibit a relative higher proliferation rate and stronger antitumor activity. Especially for their non-MHC-restricted characteristic, CIK cells have a much broader antitumor spectrum. Antibody-based therapy and CAR-T cell therapy for cancer have been demonstrated to be one of the most successful and important treatment strategies, but there are still some details to be improved. One of the key challenges is to identify suitable antigens of tumors with explicit target genes. Unfortunately, the presence of intrinsic or acquired resistance has blunted the advantages of targeted therapies, the reason is partially due to the mutation or downregulation of specific antigen (79). The immune checkpoint blockade shows impressive clinical results, but the majority of patients are either resistant or relapse after therapy (146). Based on these data, optimal adoptive cellular immunotherapy (ACI) may require a portfolio of different treatment strategies.

As mentioned earlier, CIK cells are a heterogeneous population of CD3+ T lymphocytes, which maybe not only the biggest drawback but also the biggest advantage of this method. As a heterogeneous cell population, CIK cells are proved to contain different subpopulations and present a mixed T–NK phenotype. Until now, the precise subpopulation that is the most crucial and relevant to the clinical outcome and the exact pharmacological mechanism of how CIK kill tumor cells are still not completely understood. So, it is hard to precisely evaluate the effect of the CIK cell on immune response in cancer patients and hard to know why some clinical trials with CIK failed. Clearly, this uncertainty limits the clinical application of CIK. In contrast, as a heterogeneous cell population, CIK cells are able to kill heterogeneous tumor cells despite the tumor heterogeneity and antigen escape, which are major setbacks for the antibody-based and CART immunotherapy (147). And this may be the biggest advantage of CIK therapy. CIK cells therapy can improve the prognosis of cancer patients for its safety and decreased recurrence, so it
REFERENCES

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008–2030): a population-based study. *Lancet Oncol* (2012) 13(8):790–801. doi:10.1016/ S1470-2045(12)70221-5

2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* (2010) 127(12):2893–917. doi:10.1002/ijc.25516

3. Yron I, Wood TA Jr, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. *J Immunol* (1980) 125(1):238–45.

4. Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. *J Immunol* (1980) 125(4):1487–93.

5. Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. *J Exp Med* (1991) 174(1):139–49. doi:10.1084/jem.174.1.139

6. Schmidt-Wolf IG, Leferova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. *Exp Hematol* (1993) 21(13):1673–9.

7. Kaneko T, Fusauch Y, Kakui Y, Okumura K, Mizoguchi H, Oshimi K. Cytotoxicity of cytokine-induced killer cells coated with bispecific antibody against acute myeloid leukemia cells. *Leuk Lymphoma* (1994) 14(3–4):219–29. doi:10.3109/10428199409409672

8. Zoll B, Lefterova P, Csipai M, Finke S, Trojaneck B, Ebert O, et al. Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. *Cancer Immunol Immunother* (1998) 47(4):221–6. doi:10.1007/s002620050524

9. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Leferova P, Schwella N, et al. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. *Br J Cancer* (1999) 81(6):1009–16. doi:10.1038/sj.bjc.6609800

10. Marten A, Ziske C, Schotter B, Renoth S, Weineck S, Buttgereit P, et al. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations. *J Immunother* (2001) 24(6):502–10. doi:10.1097/00002371-200111000-00007

11. Verneris MR, Karimi M, Baker J, Jayawal A, Negrin RS. Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. *Blood* (2004) 103(8):3065–72. doi:10.1182/blood-2003-06-2125

12. Jiang J, Xu N, Wu C, Deng H, Lu M, Li M, et al. Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. *Anticancer Res* (2006) 26(3B):2237–42.

13. Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachrieddy P, et al. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. *Cancer Res* (2010) 70(23):9837–45. doi:10.1158/0008-5472.CAN-10-2650

14. Hontsch C, Borck Y, Zhou H, Messmer D, Schmidt-Wolf IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). *J Cancer Res Clin Oncol* (2011) 137(2):305–10. doi:10.1007/s00432-010-0887-7

15. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG. Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. *Clin Dev Immunol* (2012) 2012:238924. doi:10.1155/2012/238924

16. Dai C, Lin F, Geng R, Ge X, Tang W, Chang J, et al. Implication of combined PD-L1/PD-1 blockade with cytokine-induced killer cells as a synergistic immunotherapy for gastrointestinal cancer. *Oncotarget* (2016) 7(19):10332–44. doi:10.18632/oncotarget.7243

17. Lee HK, Kim YG, Kim JS, Park EJ, Kim B, Park KH, et al. Cytokine-induced killer cells interact with tumor lysate-pulsed dendritic cells via CCR5 signaling. *Cancer Lett* (2016) 378(2):142–9. doi:10.1016/j.canlet.2016.05.020

18. Linn YC, Lau LC, Hui KM. Generation of cytokine-induced killer cells from leukemic samples with in vitro cytotoxicity against autologous and allogeneic leukemia blasts. *Br J Haematol* (2002) 116(1):78–86. doi:10.1046/j.1365-2457.2002.02347.x

19. Schmidt TL, Negrin RS, Contag CH. A killer choice for cancer immunotherapy. *Immunol Rev* (2014) 58(2–3):300–6. doi:10.1002/8126-014-8507-2

20. Pievevi A, Belussi C, Klein C, Rambaldi A, Golay J, Iatrana M. Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies. *Blood* (2011) 117(2):510–8. doi:10.1182/blood-2010-06-290858

21. Linn YC, Wang SM, Hui KM. Comparative gene expression profiling of cytokine-induced killer cells in response to acute myloid leukemic and acute lymphoblastic leukemia stimulators using oligonucleotide arrays. *Exp Hematol* (2005) 33(6):671–81. doi:10.1016/j.exphem.2005.03.005

22. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. *J Cancer* (2011) 2:363–8. doi:10.7150/jca.2.363

AUTHOR CONTRIBUTIONS

XG, YM, and WJ conceived this study. XG and NG wrote the manuscript. HX and LX provided critical discussion in manuscript preparation. LX and WJ revised the manuscript. All the authors reviewed this manuscript.

FUNDING

This work was supported by the National Natural Science Foundation of China (Nos. 81402063, 31400913, 81601376, and 81402850), China Postdoctoral Science Foundation funded project (2016M), the Leading Disciplines Development Government Foundation of Shaanxi, China, University’s key disciplines of molecular immunology, Doctoral research start-up fund project of Xi’an Medical University (Program Nos. 2015DOC07 and 2015DOC08). The Project was supported by the Natural Science Basic Research Plan in Shaanxi Province of China (No. 2017JM8086) and Scientific Research Program Funded by Shaanxi Provincial Education Department (15JK1636, 16JK1655).

would be the most effective treatment on residual cancer cells after conventional therapy.

Recently, much effort has been made to improve the anti-tumor activity of CIK cells and the recent findings of clinical applicability are reviewed in the paper. The promising outcomes have been made by CIK cells therapy combined with other therapies. But further research is still needed to optimize the procedure of CIK therapy. First, uniform culturing criteria should be formulated for CIK expansion. Second, more clinical trials need to be conducted with large-scale, controlled, grouped patients, including patients with different tumor stages and different cancer biomarkers. Only by doing these, can we figure out the tumor-killing mechanism of CIK cells and better evaluate their clinical efficacy.

More and more people realize that it is hard to cure cancer with only one drug or one therapeutic strategy. The combination of different drugs or therapies has already become a trend in treating heterogeneous tumors. As an effective ACI, CIK cells therapy provide a chance to prolong survival of cancer patients in clinical practice, and it is definitely worthy to spend more effort on it.

Frontiers in Immunology | www.frontiersin.org July 2017 | Volume 8 | Article 774

This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (license URL: http://creativecommons.org/licenses/by/4.0/).
23. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol (1994) 153(4):1665–96.

24. Intronna M, Franceschetti M, Ciocca A, Borleri G, Conti E, Golay J, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant (2006) 38(9):621–7. doi:10.1038/sj.bmt.3705303

25. Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Gираudo Diego L, Giraudo Diego L, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic transplant for haematological malignancies. Bone Marrow Transplant (2007) 92(7):952–9. doi:10.3324/haematol.11132

26. Li Y, Schmidt-Wolf IG, Wu YF, Huang SL, Wei J, Fang J, et al. Optimized protocols for generation of cord blood-derived cytokine-induced killer/natural killer cells. Anticancer Res (2010) 30(9):3493–9.

27. Zhang Z, Zhao X, Zhang T, Wang L, Yang L, Huang L, et al. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood. Cytotherapy (2015) 17(1):86–97. doi:10.1016/j.jcyt.2014.09.006

28. Zhang Z, Wang L, Luo Z, Zhao X, Huang J, Li H, et al. Efficacy and safety of cord blood-derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy (2015) 17(8):1130–8. doi:10.1016/j.jcyt.2015.04.002

29. Niu Q, Wang W, Li Y, Qin S, Wang Y, Wan G, et al. Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol (2011) 11(4):449–56. doi:10.1016/j.intimp.2010.12.014

30. Gao et al. CIK for Cancer Immunotherapy
Gao et al.

CIK for Cancer Immunotherapy

signaled through STAT-3 and STAT5b pathways. *Asian Pac J Cancer Prev* (2013) 14(10):5825–31. doi:10.7314/APJCP.2013.14.10.5825

59. Zhao N, Zhao MF, Rajbhandary S, Lu WY, Zhu HM, Ma L, et al. Effects and mechanism on anti-leukemic activity of cytokine-induced killer cells with an endogenous expression of interleukin-21. *Zhonghua Yi Xue Za Zhi* (2013) 93(4):293–9. doi:10.7600/cjma.js3.076-2491.2013.04.013

60. Bancheau J, Steinman RM. Dendritic cells and the control of immunity. *Nature* (1998) 392(6673):245–52. doi:10.1038/35288

61. Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, et al. Mechanistic basis for antitumor immune responses evoked by dendritic cells directly priming CD8+ T cells with alpha-NK1.1+ CD107a expressing CD4+ T cells. *Immunol Invest* (2015) 44(1):114–30. doi:10.3109/00963317.2014.985054

62. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. *Nat Med* (1999) 5(4):405–11. doi:10.1016/S1078-8952(99)93863-9

63. Nicol A, Nieda M, Koezuka Y, Porcelli S, Suzuki K, Tadokoro K, et al. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. *Immunology* (2000) 99(2):229–34. doi:10.1046/j.1365-2567.2000.00952.x

64. Cao J, Chen C, Wang Y, Chen X, Chen Z, Luo X. Influence of autologous dendritic cells on cytokine-induced killer cell proliferation, cell phenotype and antitumor activity in vitro. *Oncol Lett* (2012) 16(12):2033–7. doi:10.3892/ol.2012.139

65. Pan Y, Tao Q, Wang H, Xiong S, Zhang R, Chen T, et al. Dendritic cells decreased the concomitant expanded Tregs and Treg-related IL-15 in cytokine-induced killer cells and increased their cytotoxicity against leukemia cells. *PLoS One* (2014) 9(4):e93591. doi:10.1371/journal.pone.0093591

66. Cui Y, Yang X, Zhu W, Li J, Wu X, Pang Y. Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patients. *Oncol Lett* (2013) 6(2):537–41. doi:10.3892/ol.2013.1376

67. Shan CC, Shi LR, Ding MQ, Zhu YB, Li XD, Xu B, et al. Cytokine-induced killer cells co-cultured with dendritic cells loaded with the protein lysate produced by radiofrequency ablation induce a specific antitumor response. *Oncol Lett* (2015) 9(4):1549–56. doi:10.3892/ol.2015.2977

68. Wang YF, Kunda PE, Lin JW, Wang H, Chen XM, Liu QL, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retino- blastoma cells. *Oncol Rep* (2013) 29(5):1841–50. doi:10.3892/or.2013.2315

69. Liu Y, Liu H, He P, Li J, Liu X, Chen L, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. *Oncol Lett* (2012) 6(6):2520–5. doi:10.3892/ol.2012.2537

70. Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, Seo HG, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. *Oncol Lett* (2012) 6(6):2520–5. doi:10.3892/ol.2012.2537

71. Jung NC, Lee JH, Choi HJ, Hwang SU, Song JY, Seo HG, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. *Oncol Lett* (2012) 6(6):2520–5. doi:10.3892/ol.2012.2537

72. Lin M, Liang S, Jiang F, Xu J, Zhu W, Qian W, et al. 2003–2013, a valuable study: autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer. *Immunol Lett* (2017) 183:37–43. doi:10.1016/j.imlet.2017.01.014

73. Chen DS, Melman I. Oncology meets immunology: the cancer-immunity cycle. *Immunity* (2013) 39(1):1–10. doi:10.1016/j.immuni.2013.07.012

74. Preszler M, Lim M, Haller DA, Reardon DA, Sampson JH. Prospects of immune checkpoint modulators in the treatment of glioblastoma. *Nat Rev Neurol* (2011) 11(9):504–14. doi:10.1038/nrneurol.2015.139

75. Driessens G, Kline J, Gajewski TF. Costimulatory and coinhibitory receptors in anti-tumor immunity. *Immunol Rev* (2009) 229(1):126–44. doi:10.1111/j.1600-065X.2009.00771.x

76. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* (2012) 12(4):252–64. doi:10.1038/ncr3239

77. Vinay DS, Ryan EP, Pawelec G, Talbot WH, Stagg J, Elkord E, et al. Immune evasion in cancer: mechanistic basis and therapeutic strategies. *Semin Cancer Biol* (2015) 35(Suppl):S185–98. doi:10.1016/j.semcancer.2015.03.004

78. Poh SL, Linn YC. Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukemic blasts. *Cancer Immunol Immunother* (2016) 65(5):525–36. doi:10.1007/s00262-016-1815-8
cancer in China: a systematic review and meta-analysis. Cytotherapy (2016) 18(9):1162–77. doi:10.1016/j.jcyt.2016.05.015
98. Wang ZX, Cai YX, Liu ZF, Cui YX, Li CY, Li D, et al. Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis. World J Gastroenterol (2014) 20(4):1095–106. doi:10.3748/wjg.v20.i4.1095
99. Liang C, Xu L, Song G, Liu Z. Emerging nanomedicine approaches fighting tumor metastasis: animal models, metastasis-targeted drug delivery, phototherapy, and immunotherapy. Chem Soc Rev (2016) 45(22):6250–69. doi:10.1039/c6cs00458j
100. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 5(3):161–71. doi:10.1038/nrc1566
101. Phan JH, Moffitt RA, Stokes TH, Liu J, Young AN, Nie S, et al. Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol (2009) 27(6):350–8. doi:10.1016/j.tibtech.2009.02.010
102. Cuenca AJ, Jiang H, Hochwold SN, Delano M, Cance WG, Grobmyer SR. Emerging implications of nanotechnology on cancer diagnostics and therapeutics. Cancer (2006) 107(3):459–66. doi:10.1002/cncr.22035
103. Jin W, Cui D. Cancer nano-immunoengineering: the marriage of immunonoengineering and nanotechnology for cancer. Nano Biomed Eng (2016) 8(2):105–6. doi:10.5101/nbce.v8i2.p105-107
104. Sancic N, Marco MP. Multifunctional nanoparticles – properties and prospects for their use in human medicine. Trends Biotechnol (2008) 26(8):425–33. doi:10.1016/j.tibtech.2008.04.005
105. Yezhelyev MV, Gao X, Xing Y, Al-Hajj A, Nie S, O’Regan RM. Emerging use of nanoparticles in diagnosis and treatment of breast cancer. Lancet Oncol (2006) 7(8):657–67. doi:10.1016/S1470-2045(06)70793-8
106. Swai H, Semete B, Kalombo L, Chelule P, Kischik S, Sievers B. Nanomedicine for respiratory diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2009) 1(3):253–63. doi:10.1002/wnrn.33
107. Pison U, Welte T, Giersig M, Groneberg DA. Nanomedicine for respiratory diseases. Euer J Pharmaceut (2006) 533(1–3):341–50. doi:10.1016/j.ejphar.2005.12.068
108. Irvine DJ, Hanson MC, Rakhra K, Tokatlian T. Synthetic nanoparticles for DC-based immunotherapy. Eur J Pharmacol (2015) 770(19):11109–46. doi:10.1016/j.ejphar.2015.11.016
109. Xu LG, Xiang J, Peng R, Liu Z. Recent advances in the development of nanomaterials for DC-based immunotherapy. Sci Bull (2016) 61(7):514–23. doi:10.1211/s11434-016-1038-6
110. Cambi A, Lidke DS, Arndt-Jovin DJ, Figdor CG, Jovin TM. Ligand-conjugated quantum dots monitor antigen uptake and processing by dendritic cells. Nano Lett (2007) 7(4):970–7. doi:10.1021/nl0605093
111. Lim YT, Noh YW, Han JH, Cai QY, Yeon KH, Chung BH. Biocompatible polymer-nanoparticle-based bimodal imaging contrast agents for the label and tracking of dendritic cells. Small (2008) 4(10):1640–5. doi:10.1002/sml.200800582
112. Reichardt W, Durr C, von Elverfeldt D, Arndt-Jovin DJ, Figdor CG, Jovin TM. Methods of effective conjugation of antigens to nanoparticles as non-inflammatory vaccine formulations. Methods (2014) 60(3):232–41. doi:10.1016/j.ymeth.2013.03.036
113. Nembrini C, Stano A, Dane KY, Ballester M, van der Vlies AJ, Marsland BJ, et al. Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination. Proc Natl Acad Sci U S A (2011) 108(44):E989–97. doi:10.1073/pnas.1104264108
114. Xiang J, Wang Q, Hu Y, Liu Z, Chen X, Che Y, Li Q, et al. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytotoxic induced killer immunotherapy on function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Tumor (2016) 30(10):1221–30. doi:10.220287/10.1159/00045231
115. Li X, Dai D, Song X, Liu J, Zhu L, Xu W. Meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma. Clin Res Hepatol Gastroenterol (2014) 38(5):583–91. doi:10.1016/j.clinre.2014.04.010
116. Bu Y, Xu J, Wang X, Wang X, Wang J, Wang X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol (2012) 1(1):11. doi:10.1186/2043-3584-1-11
117. Li X, Wang C, Liu L, Du C, Cao S, Yu J, et al. Autologous cytokine-induced killer cells therapy for hepatocellular carcinoma. Gastroenterology (2015) 148(7):1383–91. doi:10.1053/j.gastro.2015.02.055
118. Chen Y, Lin WS, Zhu WF, Jin I, Zhou ZF, Huang CZ, et al. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunol Res (2016) 64(1):251–9. doi:10.1007/s12026-015-8743-0
119. Chen Y, Lin J, Guo ZQ, Lin WS, Zhou ZF, Huang CZ, et al. MHC 1-related chain a expression in gastric carcinoma and the efficacy of immunotherapy with cytokine-induced killer cells. Am J Cancer Res (2015) 5(10):3221–30. doi:10.22032/ajcr.2015.5.10.3221
120. Li X, Dai X, Shi L, Jiang Y, Chen X, Chen L, et al. Phase II/III study of radiofrequency ablation combined with cytokine-induced killer cells treating colorectal liver metastases. Cell Physiol Biochem (2016) 40(1–2):137–45. doi:10.1159/00045231
121. Wang M, Cao JX, Pan JH, Liu YS, Xu BL, Li D, et al. Adoptive immunotheraopy of cytokine-induced killer cell therapy in the treatment of non-small cell lung cancer. PloS One (2014) 9(11):e112662. doi:10.1371/journal.pone.0112662
122. Li X, Liu J, Wang Y, Chen X, Chen L, et al. Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy. Asian Pac J Cancer Prev (2014) 15(15):6009–14. doi:10.7314/ APJC.2014.15.15.6009
123. Zhao M, Li H, Li L, Zhang Y. Effects of a gemcitabine plus platinum regimen combined with a dendritic cell-cytotoxic induced killer immunotherapy on...
137. Zhang J, Zhu L, Du H, He X, Yin Y, Gu Y, et al. Autologous cytokine-induced killer cell therapy in lung cancer patients: a retrospective study. *Biomed Pharmacother* (2015) 70:248–52. doi:10.1016/j.biopha.2014.12.025

138. Zhang L, Yang X, Sun Z, Li J, Zhu H, Li J, et al. Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer. *Oncol Lett* (2016) 11(4):2605–10. doi:10.3892/ol.2016.4273

139. Jia H, Tian Y, Jiang CG, Han W. Evaluation of 29 indicators for the prognosis of advanced non-small cell lung cancer with cytokine-induced killer cell therapy combined with chemotherapy. *Exp Ther Med* (2016) 11(5):1601–10. doi:10.3892/etm.2016.1302

140. Zhao H, Wang Y, Yu J, Wei F, Cao S, Zhang X, et al. Autologous cytokine-induced killer cells improves overall survival of metastatic colorectal cancer patients: results from a phase II clinical trial. *Clin Colorectal Cancer* (2016) 15(3):228–35. doi:10.1016/j.ccc.2016.02.005

141. Lin T, Song C, Chuo DY, Zhang H, Zhao J. Clinical effects of autologous dendritic cells combined with cytokine-induced killer cells followed by chemotherapy in treating patients with advanced colorectal cancer: a prospective study. *Tumour Biol* (2016) 37(4):4367–72. doi:10.1007/s13277-015-3957-2

142. Kong DS, Nam DH, Kang SH, Lee JW, Chang JH, Kim JH, et al. Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in Korea. *Oncotarget* (2016) 8(4):7003–13. doi:10.18632/oncotarget.12273

143. Li H, Huang L, Liu LB, Wang XM, Zhang Z, Yue DL, et al. Selective effect of cytokine-induced killer cells on survival of patients with early-stage melanoma. *Cancer Immunol Immunother* (2017) 66(3):299–308. doi:10.1007/s00262-016-1939-x

144. Dutoit V, Migliorini D, Walker PR, Dietrich PY. Immunotherapy of brain tumors. *Prog Tumor Res* (2015) 42:11–21. doi:10.1159/000436986

145. Jiang J, Wu C, Lu B. Cytokine-induced killer cells promote antitumor immunity. *J Transl Med* (2013) 11:83. doi:10.1186/1479-5876-11-83

146. Minn AJ, Wherry EJ. Combination cancer therapies with immune checkpoint blockade: convergence on interferon signaling. *Cell* (2016) 165(2):272–5. doi:10.1016/j.cell.2016.03.031

147. Priceman SJ, Forman SJ, Brown CE. Smart CARs engineered for cancer immunotherapy. *Curr Opin Oncol* (2015) 27(6):466–74. doi:10.1097/CCO.0000000000000232

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.